Search PubMed⌕ Search

Biomedical subjects

M Ohta

Publications and source records attributed to M Ohta.

At least 1,063 records · Page 59Linked to original sources
PubMed1986

Value of the assay for IgA-containing circulating immune complexes in Henoch-Schönlein purpura.

Using a modified Raji cell radioimmunoassay, IgA- and IgG-containing circulating immune complexes (IgA-CIC, IgG-CIC) were examined in the sera of 10 patients with Henoch-Schönlein purpura (HSP) and compared with those in the sera of patients with systemic lupus erythematosus (SLE), erythema multiforme (EM), erythema nodosum (EN) and Schamberg's disease. The mean level of IgA-CIC in HSP (233 micrograms/ml) was statistically higher than that in samples from healthy blood donors (14 micrograms/ml; p less than 0.05). In the other diseases, the mean values of IgA-CIC (SLE, 72 micrograms/ml; EM, EN, 0 microgram/ml; Schamberg's disease, 5 micrograms/ml) were not statistically different from that of normal controls. The IgA-CIC level in HSP rose markedly during the active phase of the cutaneous manifestation (233 micrograms/ml), declining to the normal range during remission (4 micrograms/ml; p less than 0.05). On the contrary, IgG-CIC did not increase during either phase. There was an isolated patient in whom IgA-CIC seemed to correlate with the clinical events of cutaneous and systemic involvement. The timing was such that a change in the level of IgA-CIC generally preceded disease activity. These findings suggest that IgA-CIC may be an etiologic factor in the cutaneous and systemic involvements of HSP, and the laboratory test for IgA-CIC is not only useful as a research tool, but also valuable as a predictive indicator of disease activity.

Adolescent↗
PubMed1986

Coincidental pituitary adenoma and parasellar meningioma: case report.

We report a patient who had pituitary adenoma and parasellar meningioma coincidentally, with neither irradiation nor a history of head injury. Preoperative computed tomographic (CT) scan had shown a large intrasellar mass with ring-like enhancement; in contact with this mass, another well-enhanced mass had been shown. Histopathologically, the intrasellar mass was diagnosed as chromophobic pituitary adenoma and the other mass as meningotheliomatous meningioma. We present clinical, radiological, and histopathological findings and discuss previously reported cases of coincidental pituitary adenoma and meningioma without irradiation. This is the first case report since the advent of CT that pituitary adenoma and parasellar meningioma in contact with each other could be clearly demonstrated by CT.

Adenoma↗
PubMed1986

[Combination chemotherapy for bronchogenic carcinoma based on cell type].

Based on the cell types in bronchogenic carcinoma, we treated 123 patients with different regimens of combination chemotherapy. The chemotherapy regimens consisted of CAP (cyclophosphamide + adriamycin + platinum) for 60 patients with adenocarcinoma and large cell carcinoma, PP (peplomycin + platinum) for 29 patients with squamous cell carcinoma and CAV (cyclophosphamide + adriamycin + vincristine) for 35 patients with small cell carcinoma. These regimens were repeated every 4 weeks for at least 2 cycles. The response rates for CAP, PP and CAV were 18.3% (11 PR), 20.7% (6 PR) and 60% (10 CR + 11 PR), respectively. Median survival time (MST) was 12.5 months for CAP, 8.5 months for PP and 9.5 months for CAV. Responders had a significantly (P less than 0.002) improved survival (MST, 15.5 months) compared to non-responders (MST, 7.5 months) in small cell carcinoma. However, there was no significant difference between responders and non-responders in CAP and PP. Survival of patients with PS 0-1 was significantly better than that with PS 2-3 in all treated patients. Nausea and vomiting were severe in patients treated with platinum-based polychemotherapy. There was no renal failure although a transient increase of serum creatinine was noted in CAP and PP. Myelosuppression was mild to moderate in all patients treated with CAP, PP and CAV.

Adenocarcinoma↗
PubMed1986

[Embryonal carcinoma (Higuchi, Kato) of the ovary, clinical analysis and recent improvement of treatment using alpha FP as a tumor marker].

Forty-one cases of embryonal carcinoma were analyzed from a clinico-pathological point of view. The clinical stages of the patients were: 21 cases in stage I, 8 in stage II, 11 in stage III and 1 in stage IV. Survival curves were compared in accordance with clinical stages. A statistically significant difference was demonstrated between stages I and III, and a significant difference was demonstrated between stages I and II. Embryonal carcinoma in a narrow sense and yolk sac carcinoma were compared in survival curve but there were no significant differences between the two. Cases were divided into two that were pure embryonal carcinoma and embryonal carcinoma with other constituent mixtures. A comparison of these two showed that the mixed type had a better survival curve than the pure type. Effects of treatment in two different periods were compared patients who were treated in 1971-1979 belong to the 1st period group and those treated in 1979-1985 to the 2nd period group. A comparison of these two showed a much better survival curve in the 2nd period group. This difference can be attributed partly to a VAC combination chemotherapy and its maintenance for two years and partly to improvements in the operating technique such as added omentectomy and or the introduction of a second look operation. By measuring alpha FP over the whole clinical course, alpha FP was shown to be a good tumor marker reflecting the patient's condition and aggravation of the patient's condition frequently occurred around or somewhat after 15 weeks after primary surgery.

Adolescent↗
PubMed1986

[The determination of thymidylate synthetase inhibition for testing fluoropyrimidines--pharmacokinetics and metabolism of carmofur (HCFU) in patients with gynecologic malignancies--Tokai HCFU Study Group for Gynecologic Malignancies].

The pharmacokinetics and metabolism of carmofur (HCFU) were studied. Sixty-six patients were administered 100 mg of HCFU orally, and the plasma levels of the HCFU fraction (HCFUf) and 5-fluorouracil (5-FUra) were determined at 0, 1, 2, 4 and 6 hours. The average half-life of HCFUf and 5-FUra were 1.05 and 1.31 hours, and the average areas under the curves (AUC) of the plasma concentration were 6.51 hr X mcg/ml and 0.46 hr X mcg/ml, respectively. Surgical specimens of the tumors were obtained about three hours after the administration and assayed for HCFUf. 5-FUra fluorodeoxyuridine-monophosphate (FdUMP), deoxyuridine-monophosphate (dUMP), total thymidylate synthetase (TS total), and non-FdUMP-bound free enzyme (TS free). The TS inhibition rate (IR) was calculated by the follow method: IR = (TS total-TS free)/TS total X 100 levels of the TS total varied from not-detected (less than 0.10 pmol/g) to 20.5 pmol/g. The average FdUMP: dUMP ratio was 3.44 X 10(3), However, more than 80% inhibitions of TS were observed in nine cases (21.4%). The correlation indicates between TS IR and tissue FdUMP level or FdUMP: dUMP ratio were 0.57 and 0.62 in ovarian malignancies respectively. No significant correlations were observed between TS inhibition and levels of tissue 5-FUra or AUC of 5-FUra.

Antineoplastic Agents↗
PubMed1986

[Combination chemotherapy and radiation therapy for small cell carcinoma of the lung].

From January, 1982 to March, 1983, patients with small cell carcinoma of the lung were treated at Kyushu Cancer Center. Eleven patients received combination chemotherapy-radiotherapy and one patient chemotherapy alone. The chemotherapy regimen consisted of cyclophosphamide, adriamycin and vincristine which was repeated every 4 weeks for as long as possible. Radiotherapy was administered to the primary lesion and mediastinum following 2 cycles of induction chemotherapy. The overall response rate after receiving 2 cycles of chemotherapy was 75% with 4 complete (33%) and 5 partial responses (42%). After radiotherapy, response increased to 100% with 8 complete (73%) and 3 partial responses (27%). Complete response occurred in 6 of the 7 patients with limited disease and 2 of the 5 patients with extensive disease. Overall survival rate was 73% at 1 year, 36% at 2 years and 12% at 3 years with a median survival time of 21 months. Survival was better in patients with limited disease than in those with extensive disease (median survival time, 21.5 months vs. 14 months). In the 3-Year follow-up period, all patients had recurrences consisting of 4 distant, 2 local and 5 both. Myelosuppression was mild to moderate and there were no deaths related to the side effects of treatment.

Aged↗
PubMed1986

The role of surgical resection in the management of small cell carcinoma of the lung.

To assess the role of surgical resection in the management of small cell carcinoma of the lung, experience with 118 patients who were treated between 1973 and 1985 was reviewed. Twenty-five patients underwent surgical resection followed by combination chemotherapy in all except one. The remaining 93 patients were treated by combined chemotherapy and radiation therapy. The 5-year survival rate for patients with stage I disease undergoing surgical resection was 50.8%. For all 25 patients operated on, the 5-year survival rate was 30.7%. In the patients not operated on, only those with complete response had long-term survival, for whom the 5-year survival rate was 11.9%. We consider that surgical resection is definitely indicated in patients with stage I disease. If the response to initial chemotherapy is very good, patients with stage II or T3N0M0 disease also probably should receive resection. Patients with N2 disease are not candidates for resection, unless distant metastases are controlled completely by intensive chemotherapy.

Actuarial Analysis↗
PubMed1986

[Studies on hyperthermia by the use of a thermosensitizing drug].

Hyperthermic treatment using ACNU combined with a thermosensitizing drug, methylglyoxal-bis-guanylhydrazone (MGBG), was studied in human gastric cancer xenotransplanted into nude mice. In order to increase the intra-cellular MGBG content, intraperitoneal injection of alpha-difluoromethylornithine(DFMO) 1000 mg/kg was performed twice with an interval of 6 hours and 50 mg/kg of MGBG was given at the time of the second administration of DFMO. After 6 hours of MGBG administration, ACNU 20 mg/kg was given intraperitoneally and, subsequently a 23-minute hyperthermia was carried out in a water bath at 43.5 degrees C. After 48 hours a second hyperthermia was performed by the same method. Tumor weight was estimated using Battelle's Columbus Institute protocol and the inoculated tumors, which were extirpated 60 minutes after 3H-thymidine injection at a prescribed interval after cessation of hyperthermia, were assayed biochemically for the determination of DNA biosynthesis. In mice given ACNU, DFMO, MGBG plus heat, considerably superior results were obtained. Although the DFMO plus MGBG group was inferior in antitumor activity to the ACNU only or heat only group, the DFMO, MGBG plus heat group showed much the same antitumor effects, compared to the ACNU plus heat group. These data suggest that the thermosensitizing efficacy of MGBG may be applicable for clinical use.

Animals↗
PubMed1986

[Combined therapy of polyamine antimetabolite and nitrosourea in human gastric cancer].

Antitumor therapy using the polyamine antimetabolites, alpha-difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG), combined with ACNU was studied in human gastric cancer xenotransplanted into nude mice. DFMO 1,000 mg/kg (in two divided doses) and MGBG 50 mg/kg were given i.p. for 6 successive days from the time when the xenotransplanted tumor weighed about 100 mg, and ACNU 20 mg/kg was given i.p. every other day from the same time. Antitumor efficacy was assessed by the time course of tumor weight as well as of DNA biosynthesis and polyamine levels in tumor tissue. Tumor weight was estimated using Battelle's Columbus Institute protocol and DNA biosynthesis was assayed biochemically by 3H-TdR injection at a prescribed interval after termination of therapy. Furthermore, tumoral polyamine levels were assayed by HPLC. This three-drug regimen showed a favorable antitumor effect, compared to those of the other two therapies with DFMO plus MGBG as well as ACNU only. These data suggest that this combined regimen may have a synergistic efficacy judging from the action mechanisms of these three drugs.

Animals↗
PubMed1986

[Combined efficacy of polyamine antimetabolites and cis-diamminedichloroplatinum].

The combined antitumor effects of the polyamine antimetabolites, alpha-difluoro methylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG), with CDDP were studied using human gastric cancer cells xenotransplanted into nude mice. DFMO (1000 mg/kg in two divided doses) and MGBG (50 mg/kg) were given IP for six consecutive days from the time when the xenotransplanted tumor weighted about 100 mg, and CDDP (3.0 mg/kg) was given IP every other day from the same time. Animals treated with DFMO plus MGBG with or without CDDP as well as with CDDP only displayed suppressed tumor growth, compared to untreated mice. In mice treated with these three drugs, however, tumor growth was rather rapid compared to those treated with CDDP only, although tumoral CDDP levels in animals given DFMO, MGBG and CDDP were higher than those given CDDP only. When DFMO, MGBG and CDDP or DFMO and MGBG were administered, tumoral spermidine and spermine levels decreased markedly. On the other hand, tumor DNA biosynthesis in the CDDP only group dropped markedly 24 hours after the termination of therapy. These results suggest that an alteration in the DNA structure caused by polyamine deficiency may prevent cross-link formation in DNA by CDDP.

Animals↗
PubMed1986

Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-I, -S, -M and -K) with capabilities of monocyte-macrophage lineage differentiation and constitutive production of interleukin 1.

Four monocytoid cell lines, JOSK-I, -S, -M, and -K, were newly established successfully from peripheral blood of two cases of acute monocytic leukemia and one case each of acute myelomonocytic leukemia and chronic myelogenous leukemia in myelomonocytic blast crisis. In order to establish permanent cell lines, cultures of leukemic blasts were initiated in 96-well microtiter plates. Each cell line grew in a suspension culture with a doubling time of 24-32 h and has been serially maintained for over 20 mo. Each line had immature monocytic properties as judged from the results of cytological, immunochemical, and functional analyses. The cells showed a positive reaction for alpha-naphthyl butyrate esterase which was completely inhibited by sodium fluoride and exhibited immature monocytic features on electron microscopic observation. They also had surface markers specific for the monocyte-macrophage lineage. Chromosome analyses showed that each line had a variety of marker chromosomes; furthermore, these established lines exhibited high potentialities involving morphological and functional differentiation into more mature monocytic cells when induced by several chemical inducers. We also found that two of the established cell lines produced much interleukin 1 activity without any stimuli. These new lines might be valuable for studying the regulation of monocyte-macrophage differentiation and host defense mechanisms.

Aged↗
PubMed1986

Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents.

The process of rejection of skin first-set-allograft transplantation was pursued by observing the microcirculation of living mice, in comparison with that of the isograft transplantation (BALB/C vs. BALB/C). The vascular connection of the skin allograft between the host (BALB/C) and graft (R III) was established on day 8, in just the same pattern as in isograft skin, but the blood flow slowed down on day 9, and the formation of microthrombi was observed in the arterioles and later in the venules and capillaries at the sites slightly inside the graft from the margin on day 10. Thereafter each small vessel of the host formed a loop and the blood flow from the host did not enter the graft. The thrombus formation was confirmed by light and electron microscopy. The importance of the thrombus formation in the rejection process was further strengthened by prolongation of the cessation of the blood flow at the boundary from day 10 to days 14-15, after daily administration from days 2 to 9 of OKY-1581 (0.4 mg/g i.p.), a selective thromboxane synthetase inhibitor, or ticlopidine (0.3 mg/10 g p.o.), an inhibitor of platelet aggregation, in combination with a subthreshold dose (0.4 mg/10 g i.p.) of azathioprine. None of these drugs alone significantly prolonged the survival time.

Acrylates↗